In 2023, the STEP-HFpEF trial showed that semaglutide, a once-weekly long-acting GLP-1 RAs, significantly improved exercise capacity, enhanced quality of life, and notably reduced body weight while mitigating inflammation over 52 weeks in obese patients with HFpEF compared to placebo [9]
In some cases, people might experience dizziness, headache, or an allergic reaction
A study using oral administration of ethanol extract of MO leaves (500 mg/kg) and glibenclamide (0.5 mg/kg) as a reference drug measured fasting blood glucose and glucose tolerance
Manufacturers with strong cardiometabolic data and scalable production are likely to gain advantage as payers review access across diabetes and obesity indications. GLP-1 Receptor Agonist Market Value Analysis The GLP-1 receptor agonist market is moving from diabetes-centered prescribing toward broader cardiometabolic disease management
The findings matched the results seen in umbilical cord samples of babies who were exposed to Tylenol before birth in support of the conclusion that Tylenol use can lead to neurodevelopmental issues such as autism and ADHD
.jpg)
